Home > Boards > US OTC > Miscellaneous >

Proteonomix Inc. (PROT)

Add PROT Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 7/7/2017 9:51:47 AM - Followers: 57 - Board type: Free - Posts Today: 0

 Proteonomix Inc. (PROT)


The Company for Life's Journey







Company Information:

187 Mill Lane
Mountainside, NJ 07092

Phone: 973-544-6116

Fax: 973-833-0277

E-mail: info@proteonomix.com



CIK:  0001469559


Proteonomix, Inc., We are a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives with an initial focus on diabetes and cardiac diseases. Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These diseases include, but are not limited to, cancer, heart disease, diabetes, and autoimmune conditions. Stem cell therapy provides much promise for the treatment of diseases previously regarded as incurable.

Our mission is to achieve a leadership position in life enhancement regenerative stem cell therapies, services, and products through a combination of first to market technologies, and innovative clinical trial strategies.

1. Through our operating subsidiary, National Stem Cell, we have developed a catalog of intellectual properties and patent applications. These technologies are designed to work together in a synergistic fashion. Our initial focus in stem cell therapeutics is to achieve a leadership position in:

  • a. the development of identification biomarkers (a biomarker is a substance used as an indicator of a biological state which refers to the complete range of genes found in biological structure and processes of the living body, including the nervous system, the endocrine system, and our senses of sight, hearing, taste, smell, and touch. It is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention) cell derivatives, and cellular proteins.
  • b. the development of stem cell therapies for disease and injury; and
  • c. the performance of reproductive cell/tissue laboratory services.

We need to test its technologies and therapies before commercialization.
We have identified stem cells in the human pancreas and have applied for patents for cell surface markers (the molecules present on the surface of each cell which define the cell on what receptors are present - a technique often used to associate cells with certain immune functions) for these pancreatic stem cells as well as methods for their isolation. Based on the fact that these cells are autologous (from same person) rather than from a non-related donor, we anticipate that the cells that we are able to isolate will substantially reduce rejection when transplanted into the liver of the same diabetic patient. The company is performing further research in this area with the University of Miami.

2. Through National Stem Cell, we have developed a patent-pending container device for cryopreservation of stem cells (the process where cells are preserved by cooling to low sub-zero temperatures) that we believe will provide significant improvements in viable cell recovery and contaminant protection, both in freezing and thawing stem cells, than is found with cryostorage containers currently in use.

3. Multiple cosmetic products have been developed. The products are based on our patents describing our Secreted Matrix TM technology. These products are in production and their launch is scheduled for the beginning of 2010.

4.Laboratory services are provided by our wholly owned, accredited and operating reproductive cell/tissue banking service (sperm, ova, ovarian tissue, testicular tissue and embryos). It is anticipated that our laboratory services will provide advanced technologies and procedures for the collection, laboratory testing, bio-genetic typing, processing and cryogenic storage of stem cells from both umbilical cord and peripheral blood. Umbilical cord blood stem cells and reproductive cells are processed and banked for both allogeneic (transfer from one person to another) and autologous (derived from and used by the same individual) therapeutic transplantation for a variety of medical disorders, including leukemia and lymphoma with stem cells and infertility with sperm cells. We have developed and implemented a unique, effective and comprehensive strategy for the marketing of our services and products on a national and international scale for applications in stem cell therapeutics together with cell-tissue laboratory services.



Michael Cohen, CEO

Kenneth Steiner, COO

Ian McNiece, CSO

Robert Kohn

Steven Byle, Secretary


Important Company Highlights: 

Proteoderm, our latest product. 




Recent News: 



News of particular importance:
November 11, 2011 @4:00 PM
Proteonomix, Inc. (PROT) Announces That Its Subsidiary Proteoderm, Inc. Has Received the Approval of Its Application for INCI...

PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the Cosmetic Ingredients Review Board ("CIR") has approved and assigned an INCI nomenclature to its innovative Matrix NC-138 Cosmeceutical product, a necessary final step prior to manufacturing and commercialization of cosmetic products in the United States.

Michael Cohen, President of the Company, stated: "The approval of the CIR and its issuance of an INCI name to our Matrix NC-138 is a significant and momentous occasion. We have now demonstrated that we are committed to develop and deliver to the market safe and innovative products. The issuance of the INCI name will allow the company to move forward with commercialization of our cosmeceutical product, Proteoderm NC-138 in the USA."

Proteoderm Inc. has developed a line of anti-aging skin care cosmetics based on its research with stem cell derivatives. We are the first company to use a matrix of proteins ("Matrix NC-138") originally discovered in non-embryonic stem cells, to harness the anti-aging potential in cosmeceutical products.

Mr. Cohen continued: "We anticipate that our efforts to market the product and partner up with other cosmetic manufacturers will be greatly enhanced by the issuance of an INCI name."

Based in Washington, D.C., the Personal Care Product Council ("PCPC") has funded the Cosmetic Ingredient Review ("CIR") Expert Panel as an independent, nonprofit panel of scientists and physicians established in 1976 to assess the safety of ingredients used in cosmetics in the U.S. with the support of the U.S. Food and Drug Administration and the Consumer Federation of America in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. The CIR mission is to review and assess the safety of ingredients used in cosmetics in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. Upon conclusion of its review the CIR issues an International Nomenclature of Cosmetic Ingredients ("INCI") name to the ingredient. The PCPC does not regulate but provides information on national and international regulation. We presently adhere to the Personal Care Products Council Consumer Commitment Code, including filing timely reports with the FDA regarding manufacturing and ingredient usage.


Feb 18, 2010 08:30 ET

Proteonomix, Inc. (PROT) Announces the Formation of StromaCel, Inc.

Proteonomix, Inc. (PINKSHEETS: PROT) announces that it has formed a wholly-owned subsidiary, StromaCel, Inc.


The mission of StromaCel is to develop therapies using stromal cells. Stromal cells are key components of tissues and provide critical cytokines and growth factors as well as the cellular microenvironment for normal homeostasis. A cytokine is a small protein released by cells that affects the interactions and communications between cells and the behavior of cells. A growth factor is a naturally occurring substance capable of stimulating cellular growth, proliferation and differentiation. Homeostasis is a self-regulating process by which a biological system maintains stability while adjusting to changing conditions. Stromal cells provide a niche proliferation environment for stem cells.


StromaCel's goal is to study the basic cellular properties of stromal cells and to identify the utility of cellular and protein derivatives in disease repair.


StromaCel is the fifth subsidiary of Proteonomix. National Stem Cell, Inc. is Proteonomix' operating subsidiary. The Sperm Bank of New York, Inc., engaged in reproductive tissue banking, including sperm, ova, ovarian tissue and testicular tissue, is a subsidiary of National Stem Cell, Inc. Proteoderm has developed and has begun to manufacture and distribute a line of anti-aging cosmeceuticals based on stem cell derivatives. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Going forward, Proteonomix intends to create and dedicate a subsidiary to each of its technologies.


Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteonomix has facilities at a number of academic institutions. Please visit www.proteonomix.com, www.proteoderm.com, www.pinksheets.com and www.sec.gov for further information about the Company.


Certain statements contained herein are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that the statements made in this press release relating to the mission statement of StromaCel constitute forward-looking statements and makes no guarantees of future performance and actual results or developments may differ materially from projections in forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the time the statements are made.








Transfer Agent:

Olde Monmouth Stock Transfer Co., Inc.
200 Memorial Pkwy
Atlantic Highlands 07716




Share Structure:

Outstanding Common Shares

  7,910,556 a/o August 20, 2012

5,155,665  as of Nov 4, 2011

Authorized Shares

240,000,000 as of Nov 4, 2011



Investor Relations:







All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.


Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn't a sign of endorsement.


Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp




Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PROT News: Proteonomix Settles Litigation 04/01/2013 01:01:00 PM
PROT News: Proteonomix Announces Extension Of Deadline 01/14/2013 09:45:00 AM
PROT News: Proteonomix To Require Physical Exchange Of Certificates 01/10/2013 11:49:00 AM
PROT News: Proteonomix To Require Physical Exchange Of Certificates 01/10/2013 11:49:00 AM
PROT News: Proteonomix Announces Restructuring 01/08/2013 09:42:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#3718   There's a pump out this AM. joeeasy 07/07/17 09:51:47 AM
#3717   Any idea what is propelling PROT today? buxmaker 07/07/17 09:41:06 AM
#3716   nah, somebody sneezed and some change fell out mongoose64801 02/10/17 05:34:36 PM
#3715   Awoke. a surfer 02/10/17 05:28:35 PM
#3714   nothing will happen. absolutely nothing. InvestorStemCell 07/13/15 05:42:28 PM
#3706   Just checked the clinical trials website and looks WestMaui76 06/12/15 03:10:45 PM
#3705   Do you happen to have a copy of Bayutiger 05/17/15 10:03:58 AM
#3704   You are exactly correct. Looking back with mongoose64801 05/06/15 08:25:26 AM
#3703   That's the sanction on the Administrative hearing only. Mo_Jo 05/06/15 12:19:18 AM
#3702   again, not much. gotta know when to vuduu 05/02/15 12:52:38 PM
#3700   So what we see here is that the mongoose64801 04/10/15 12:16:12 PM
#3699   PROT: SEC Admin Proceeding against CEO: Renee 04/10/15 09:30:17 AM
#3698   On the Gov. site the liver trial has mongoose64801 02/20/15 01:01:41 PM
#3697   The trials are real and ongoing. One foggdogg 02/20/15 12:38:44 PM
#3696   There is no reason to believe that we mongoose64801 02/20/15 11:26:02 AM
#3695   When are we going to say 'welcome back' WillAnderz 02/20/15 02:40:27 AM
#3694   They took the stem cell IP of the Super Dave 02/20/15 12:33:13 AM
#3693   But he is gone:"Cohen also has agreed to Dina 02/19/15 11:32:18 PM
#3692   Yes, feel free to move on. Super Dave 02/19/15 09:41:05 PM
#3691   Oh please. Let's face the facts. mongoose64801 02/19/15 09:30:49 PM
#3690   On the bright side, this is about shuffling Super Dave 02/19/15 09:09:55 PM
#3689   PROT: SEC Charges New Jersey Biotechnology Company and Renee 02/19/15 04:06:12 PM
#3688   This, as I understand it, is a personal rubs1 02/15/15 10:23:38 PM
#3687   Shareholders of Proteonomix Inc. Potential claims for losses Dina 02/05/15 01:28:39 PM
#3686   Curious as to why such a large bid rubs1 01/14/15 11:29:32 AM
#3685   That is what I have gathered from these OhManIDied 01/10/15 03:35:14 PM
#3684   But alas, it seems that the rights/ownership of Dina 01/10/15 03:22:05 PM
#3683   Have any of the early investors here, prior OhManIDied 01/10/15 01:56:37 PM
#3680   I agree. I think that is a plausible timeline. playstay77 01/07/15 10:29:35 AM
#3679   Here's another option to try and dig up WestMaui76 01/06/15 05:19:36 PM
#3678   Also, here is a link to the last WestMaui76 01/06/15 05:10:15 PM
#3677   Here is a link that will take you WestMaui76 01/06/15 05:03:51 PM
#3676   I have no idea what is going on rubs1 01/02/15 07:22:50 AM
#3673  Restored Last updated: September 25, 2014 Dina 01/01/15 09:59:51 PM
#3672  Restored 10m o/s, $.012, 120k market cap, many patents Dina 01/01/15 09:59:12 PM
#3671   I would expect some updates to be done rubs1 12/01/14 08:32:14 PM
#3670   Has anyone checked on the status of either rubs1 11/15/14 09:05:59 AM
#3669   I do not think there are any assets, rubs1 10/21/14 11:22:56 AM
#3668   I hope somebody knows a name of a Yachtsy 10/19/14 03:58:02 AM
#3667   That information has not been updated in quite rubs1 10/17/14 02:07:26 PM
#3666   The phone number listed on that website is WestMaui76 10/09/14 05:37:53 PM
#3665   I guess the truth hurts, another 0 volume day jeagerboy 09/30/14 05:21:35 PM
#3662   LMAO, look at the little chart above that jeagerboy 09/29/14 09:54:23 PM
#3661   Look a little harder. ENRTfan 09/29/14 02:03:38 PM
#3660   Please give me the details on your DD. rubs1 09/29/14 09:41:48 AM
#3659   Not much of a website, but the Stromacel foggdogg 09/29/14 04:07:51 AM
#3658   DD is telling me this POS is a jeagerboy 09/27/14 08:36:46 AM
#3657   Anyone notice when the website went down? WestMaui76 09/26/14 03:08:37 PM
#3656   What are you talking about???? This company ENRTfan 09/25/14 11:22:00 PM
#3651   Please explain.... rubs1 09/20/14 10:45:57 AM